Docality.com Logo
 
Dr. Jane  Wright  Dds,Ms image

Dr. Jane Wright Dds,Ms

7851 Cooper Rd
Kenosha WI 53142
262 945-5272
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 6374-15
NPI: 1053604777
Taxonomy Codes:
1223X0400X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

None Found

Publications

Maxillary lateral incisor agenesis and its relationship to overall tooth size. - The Journal of prosthetic dentistry
Agenesis of the maxillary lateral incisor has been linked to differences in the size of the remaining teeth. Thus, the mesiodistal space required for definitive esthetic restoration in patients with missing maxillary lateral incisors may be reduced.The purpose of this study was to determine whether a tooth size discrepancy exists in orthodontic patients with agenesis of one or both maxillary lateral incisors.Forty sets of dental casts from orthodontic patients (19 men and 21 women; mean 15.9 years of age; all of European origin) were collected. All casts had agenesis of one or both maxillary lateral incisors. Teeth were measured with a digital caliper at their greatest mesiodistal width and then compared with those of a control group matched for ethnicity, age, and sex. Four-factor ANOVA with repeated measures of 2 factors was used for statistical analysis (α=.05).Orthodontic patients with agenesis of one or both maxillary lateral incisors exhibited smaller than normal tooth size compared with the control group. The maxillary arch had a larger tooth size difference between the control and test groups than the mandibular arch (there was a significant Jaw×Group interaction [F=4.78, P=.032]).Agenesis of one or both maxillary lateral incisors is significantly associated with tooth size discrepancy, which may affect the space remaining for restoration of the remaining teeth.Copyright © 2016 Editorial Council for the Journal of Prosthetic Dentistry. Published by Elsevier Inc. All rights reserved.
Synthesis and structure-activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter. - Bioorganic & medicinal chemistry letters
The synthesis and SAR of 4-methoxy-3-(piperidin-4-yl) benzamides identified after a high-throughput screen of the MLPCN library is reported. SAR was explored around the 3-piperidine substituent as well as the amide functionality of the reported compounds. Starting from the initial lead compounds, 1-7, iterative medicinal chemistry efforts led to the identification of ML352 (10m). ML352 represents a potent and selective inhibitor of CHT based on a drug-like scaffold.Copyright © 2015 Elsevier Ltd. All rights reserved.
Identification and characterization of ML352: a novel, noncompetitive inhibitor of the presynaptic choline transporter. - ACS chemical neuroscience
The high-affinity choline transporter (CHT) is the rate-limiting determinant of acetylcholine (ACh) synthesis, yet the transporter remains a largely undeveloped target for the detection and manipulation of synaptic cholinergic signaling. To expand CHT pharmacology, we pursued a high-throughput screen for novel CHT-targeted small molecules based on the electrogenic properties of transporter-mediated choline transport. In this effort, we identified five novel, structural classes of CHT-specific inhibitors. Chemical diversification and functional analysis of one of these classes identified ML352 as a high-affinity (Ki = 92 nM) and selective CHT inhibitor. At concentrations that fully antagonized CHT in transfected cells and nerve terminal preparations, ML352 exhibited no inhibition of acetylcholinesterase (AChE) or cholineacetyltransferase (ChAT) and also lacked activity at dopamine, serotonin, and norepinephrine transporters, as well as many receptors and ion channels. ML352 exhibited noncompetitive choline uptake inhibition in intact cells and synaptosomes and reduced the apparent density of hemicholinium-3 (HC-3) binding sites in membrane assays, suggesting allosteric transporter interactions. Pharmacokinetic studies revealed limited in vitro metabolism and significant CNS penetration, with features predicting rapid clearance. ML352 represents a novel, potent, and specific tool for the manipulation of CHT, providing a possible platform for the development of cholinergic imaging and therapeutic agents.
Functional characterization of C. elegans Y-box-binding proteins reveals tissue-specific functions and a critical role in the formation of polysomes. - Nucleic acids research
The cold shock domain is one of the most highly conserved motifs between bacteria and higher eukaryotes. Y-box-binding proteins represent a subfamily of cold shock domain proteins with pleiotropic functions, ranging from transcription in the nucleus to translation in the cytoplasm. These proteins have been investigated in all major model organisms except Caenorhabditis elegans. In this study, we set out to fill this gap and present a functional characterization of CEYs, the C. elegans Y-box-binding proteins. We find that, similar to other organisms, CEYs are essential for proper gametogenesis. However, we also report a novel function of these proteins in the formation of large polysomes in the soma. In the absence of the somatic CEYs, polysomes are dramatically reduced with a simultaneous increase in monosomes and disomes, which, unexpectedly, has no obvious impact on animal biology. Because transcripts that are enriched in polysomes in wild-type animals tend to be less abundant in the absence of CEYs, our findings suggest that large polysomes might depend on transcript stabilization mediated by CEY proteins.© The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic Acids Research.
Genetic targeting of the amphetamine and methylphenidate-sensitive dopamine transporter: on the path to an animal model of attention-deficit hyperactivity disorder. - Neurochemistry international
Alterations in dopamine (DA) signaling underlie the most widely held theories of molecular and circuit level perturbations that lead to risk for attention-deficit hyperactivity disorder (ADHD). The DA transporter (DAT), a presynaptic reuptake protein whose activity provides critical support for DA signaling by limiting DA action at pre- and postsynaptic receptors, has been consistently associated with ADHD through pharmacological, behavioral, brain imaging and genetic studies. Currently, the animal models of ADHD exhibit significant limitations, stemming in large part from their lack of construct validity. To remedy this situation, we have pursued the creation of a mouse model derived from a functional nonsynonymous variant in the DAT gene (SLC6A3) of ADHD probands. We trace our path from the identification of these variants to in vitro biochemical and physiological studies to the production of the DAT Val559 mouse model. We discuss our initial findings with these animals and their promise in the context of existing rodent models of ADHD.Copyright © 2013 Elsevier Ltd. All rights reserved.
Transgenic overexpression of the presynaptic choline transporter elevates acetylcholine levels and augments motor endurance. - Neurochemistry international
The hemicholinium-3 (HC-3) sensitive, high-affinity choline transporter (CHT) sustains cholinergic signaling via the presynaptic uptake of choline derived from dietary sources or from acetylcholinesterase (AChE)-mediated hydrolysis of acetylcholine (ACh). Loss of cholinergic signaling capacity is associated with cognitive and motor deficits in humans and in animal models. Whereas genetic elimination of CHT has revealed the critical nature of CHT in maintaining ACh stores and sustaining cholinergic signaling, the consequences of elevating CHT expression have yet to be studied. Using bacterial artificial chromosome (BAC)-mediated transgenic methods, we generated mice with integrated additional copies of the mouse Slc5a7 gene. BAC-CHT mice are viable, appear to develop normally, and breed at wild-type (WT) rates. Biochemical studies revealed a 2 to 3-fold elevation in CHT protein levels in the CNS and periphery, paralleled by significant increases in [(3)H]HC-3 binding and synaptosomal choline transport activity. Elevations of ACh in the BAC-CHT mice occurred without compensatory changes in the activity of either choline acetyltransferase (ChAT) or AChE. Immunohistochemistry for CHT in BAC-CHT brain sections revealed markedly elevated CHT expression in the cell bodies of cholinergic neurons and in axons projecting to regions known to receive cholinergic innervation. Behaviorally, BAC-CHT mice exhibited diminished fatigue and increased speeds on the treadmill test without evidence of increased strength. Finally, BAC-CHT mice displayed elevated horizontal activity in the open field test, diminished spontaneous alteration in the Y-maze, and reduced time in the open arms of the elevated plus maze. Together, these studies provide biochemical, pharmacological and behavioral evidence that CHT protein expression and activity can be elevated beyond that seen in wild-type animals. BAC-CHT mice thus represent a novel tool to examine both the positive and negative impact of constitutively elevated cholinergic signaling capacity.Copyright © 2013 Elsevier Ltd. All rights reserved.
RNA-binding protein GLD-1/quaking genetically interacts with the mir-35 and the let-7 miRNA pathways in Caenorhabditis elegans. - Open biology
Messenger RNA translation is regulated by RNA-binding proteins and small non-coding RNAs called microRNAs. Even though we know the majority of RNA-binding proteins and microRNAs that regulate messenger RNA expression, evidence of interactions between the two remain elusive. The role of the RNA-binding protein GLD-1 as a translational repressor is well studied during Caenorhabditis elegans germline development and maintenance. Possible functions of GLD-1 during somatic development and the mechanism of how GLD-1 acts as a translational repressor are not known. Its human homologue, quaking (QKI), is essential for embryonic development. Here, we report that the RNA-binding protein GLD-1 in C. elegans affects multiple microRNA pathways and interacts with proteins required for microRNA function. Using genome-wide RNAi screening, we found that nhl-2 and vig-1, two known modulators of miRNA function, genetically interact with GLD-1. gld-1 mutations enhance multiple phenotypes conferred by mir-35 and let-7 family mutants during somatic development. We used stable isotope labelling with amino acids in cell culture to globally analyse the changes in the proteome conferred by let-7 and gld-1 during animal development. We identified the histone mRNA-binding protein CDL-1 to be, in part, responsible for the phenotypes observed in let-7 and gld-1 mutants. The link between GLD-1 and miRNA-mediated gene regulation is further supported by its biochemical interaction with ALG-1, CGH-1 and PAB-1, proteins implicated in miRNA regulation. Overall, we have uncovered genetic and biochemical interactions between GLD-1 and miRNA pathways.
Clinical supervision: a review of the evidence base. - Nursing standard (Royal College of Nursing (Great Britain) : 1987)
This article examines the concept of clinical supervision in nursing and considers how it is defined. It reviews the evidence supporting clinical supervision and discusses whether the introduction of clinical supervision may have been an example of a nursing 'fashion' or 'fad'. It also discusses whether reflection, as part of clinical supervision, has drawbacks as well as benefits. The author concludes that clinical supervision was implemented by the nursing profession without a sound evidence base.
RNA-based regulation of pluripotency. - Trends in genetics : TIG
Pluripotent cells have the unique ability to differentiate into diverse cell types. Over the past decade our understanding of the mechanisms underlying pluripotency, and particularly the role of transcriptional regulation, has increased dramatically. However, there is growing evidence for 'RNA-based' regulation of pluripotency. We use this term to describe control of gene expression by RNA-binding proteins (RBPs) and regulatory non-coding RNAs (ncRNAs). These molecules bind to specific elements within mRNAs and, by recruiting various effectors, affect many aspects of mRNA regulation. Here, we discuss the role of RBPs and ncRNAs in both the induction and maintenance of pluripotency. We highlight and contrast examples from pluripotent cell lines and in vivo systems while discussing the connection to transcriptional regulators.Copyright © 2012 Elsevier Ltd. All rights reserved.
Defective presynaptic choline transport underlies hereditary motor neuropathy. - American journal of human genetics
The neuromuscular junction (NMJ) is a specialized synapse with a complex molecular architecture that provides for reliable transmission between the nerve terminal and muscle fiber. Using linkage analysis and whole-exome sequencing of DNA samples from subjects with distal hereditary motor neuropathy type VII, we identified a mutation in SLC5A7, which encodes the presynaptic choline transporter (CHT), a critical determinant of synaptic acetylcholine synthesis and release at the NMJ. This dominantly segregating SLC5A7 mutation truncates the encoded product just beyond the final transmembrane domain, eliminating cytosolic-C-terminus sequences known to regulate surface transporter trafficking. Choline-transport assays in both transfected cells and monocytes from affected individuals revealed significant reductions in hemicholinium-3-sensitive choline uptake, a finding consistent with a dominant-negative mode of action. The discovery of CHT dysfunction underlying motor neuropathy identifies a biological basis for this group of conditions and widens the spectrum of disorders that derive from impaired NMJ transmission. Our findings compel consideration of mutations in SLC5A7 or its functional partners in relation to unexplained motor neuronopathies.Copyright © 2012 The American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Map & Directions

7851 Cooper Rd Kenosha, WI 53142
View Directions In Google Maps

Nearby Doctors

10400 75Th St
Kenosha, WI 53142
262 487-7010
6148 106 Th Ave.
Kenosha, WI 53142
606 260-0235
8500 75Th St Suite 101
Kenosha, WI 53142
262 532-2260
6127 Green Bay Rd #200
Kenosha, WI 53142
262 583-3706
10400 75Th St Aurora Medical Center
Kenosha, WI 53142
262 977-7000
5703 75Th St
Kenosha, WI 53142
262 971-1363
6123 Green Bay Rd Suite 120
Kenosha, WI 53142
262 522-2710
5707 75 Street
Kenosha, WI 53142
262 970-0321
6125 Green Bay Rd Suite 700
Kenosha, WI 53142
262 548-8633
11300 75Th St
Kenosha, WI 53142
262 091-1039